These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36322325)

  • 1. Trends and Characteristics of New Drug Approvals in China, 2011-2021.
    Su L; Liu S; Li G; Xie C; Yang H; Liu Y; Yin C; Chen X
    Ther Innov Regul Sci; 2023 Mar; 57(2):343-351. PubMed ID: 36322325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the new drug access gap between China and the United States and its related policies.
    Zhu X; Chen Y
    Front Pharmacol; 2023; 14():1296737. PubMed ID: 38259295
    [No Abstract]   [Full Text] [Related]  

  • 6. Research and development of mAb drugs in China: a look from policy perspectives.
    Jiang R; Sun Y; Ung C; Dong X; Kong X; Hu Y; Shao R
    Hum Vaccin Immunother; 2019; 15(11):2695-2705. PubMed ID: 31116629
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.
    Peng F; Zheng H
    Ther Innov Regul Sci; 2023 Nov; 57(6):1314-1321. PubMed ID: 37651044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Drug Conditional Approval Process in China: Challenges and Opportunities.
    Yao X; Ding J; Liu Y; Li P
    Clin Ther; 2017 May; 39(5):1040-1051. PubMed ID: 28431767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reimbursement decision speed for oncology new drugs in China and its determinant factors.
    Zhu X; Chen Y
    Front Public Health; 2023; 11():1207739. PubMed ID: 38026304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The year's new drugs and biologics 2019.
    Graul AI; Pina P; Tracy M; Sorbera L
    Drugs Today (Barc); 2020 Jan; 56(1):47-103. PubMed ID: 32055805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosis.
    Kang Q; Hu J; Yang N; He J; Yang Y; Tang M; Jin C
    Intractable Rare Dis Res; 2019 Aug; 8(3):165-171. PubMed ID: 31523593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The drug lag issue: a 20-year review of China.
    Li X; Yang Y
    Invest New Drugs; 2021 Oct; 39(5):1389-1398. PubMed ID: 33928468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.